Journal article
Vaniprevir: HCV NS3/4A protease inhibitor treatment of hepatitis C
Drugs of the Future, Vol.35(10), pp.803-813
2010
Abstract
Protease inhibitors are among a number of new classes of direct-acting antivirals for hepatitis C which, when combined with conventional peginterferon alfa/ribavirin or with other classes of direct-acting antivirals, offer the potential to vastly improve disease outcomes for affected individuals. Early evaluations imply that a number of these agents are well tolerated and produce encouraging rapid declines in plasma viral load. Concerns relate to the rapid development of drug resistance, with resulting viral rebound. Vaniprevir (MK-7009) is a novel inhibitor of genotype 1 proteases with some potency against genotype 2 currently undergoing phase II trials.
Details
- Title
- Vaniprevir: HCV NS3/4A protease inhibitor treatment of hepatitis C
- Authors/Creators
- E. Hammond (Author/Creator)A. Lucas (Author/Creator)M. Lucas (Author/Creator)E. Phillips (Author/Creator)S. Gaudieri (Author/Creator)
- Publication Details
- Drugs of the Future, Vol.35(10), pp.803-813
- Publisher
- Prous Thomson Reuters
- Identifiers
- 991005543198207891
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
46 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 3 Agriculture, Environment & Ecology
- 3.85 Food Science & Technology
- 3.85.99 Cereal Starch Properties
- Web Of Science research areas
- Genetics & Heredity
- ESI research areas
- Molecular Biology & Genetics